AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning at page 3, line 9, with the following rewritten paragraph:

[0005] On the other hand, an α-glucosidase inhibitor is a drug having an action inhibiting a digestive enzyme such as an amylase, a maltase, an α-dextrinase~~α-dexitrinase~~, or a sucrase and retarding digestion and absorption of starch or sucrose; and has been widely known as an agent for the prophylaxis or treatment of diabetes.

Please replace the paragraph beginning at page 14, line 7, with the following rewritten paragraph:

[0028] The α-glucosidase inhibitor used in the present invention may be a drug having an action delaying digestion and absorption of starch or sucrose by inhibiting a digestive enzyme such as amylase, maltase, an α-dextrinase~~α-dexitrinase~~, and sucrase. Examples of such an α-glucosidase inhibitor may include voglibose, acarbose, miglitol, emiglitate, salts thereof, and the like. Examples of the salts thereof may include the salts exemplified in the paragraph of the salt of the fibrate compound (e.g., a physiologically or pharmaceutically acceptable salt), and others. Incidentally, the α-glucosidase inhibitor may also include a derivative (e.g., an ester) or prodrug of the above-exemplified α-glucosidase inhibitor. These α-glucosidase inhibitors may be used singly or in combination. Among the α-glucosidase inhibitors, voglibose, acarbose, and the like are particularly preferred.

Please replace the paragraph beginning at page 18, line 12, with the following rewritten paragraph:

[0035] The dosage form of the pharmaceutical composition (or pharmaceutical preparation) is not particularly limited to a specific one, and may be any one of a liquid

preparation (e.g., a suspension, an emulsion, a syrup, an injection, a jelly, and a gumdrop-like preparation~~gumi~~), a semi-solid preparation (e.g., an ointment such as a soft ointment, or a hard ointment), a solid preparation [e.g., a fine powder, a subtle granule, a powder, a granule, a pill (ball), a capsule (e.g., a hard capsule, and a soft capsule), a tablet, an compression preparation, and a fused and solidified preparation].

Please replace the paragraph beginning at page 18, line 22, with the following rewritten paragraph:

[0036] Moreover, the mode (or manner) of administration of the pharmaceutical composition of the present invention is not particularly limited to a specific one, and may be any form of oral administration or non-oral administration. Among the pharmaceutical compositions, the oral preparation may include, for example, a granule (including a dry syrup), a powder, a tablet (including a buccal, an oral disintegrant, a lozenge (trochiscuss), and a chewable tablet), a capsule (including a soft capsule and a microcapsule), a syrup, an emulsion, a suspension, a jelly, a gumdrop-like preparation~~gumi~~, and others. Incidentally, the oral preparation may also include a preparation controlling release of the active ingredients in the body with a known preparation component (e.g., an immediate (rapid) release preparation, and a sustained release preparation). Moreover, examples of the non-oral preparation may include an injection (including a subcutaneous injection, an intravenous injection, an intramuscular injection, an intraperitoneal injection, and a drip infusion), an external preparation (including a nasal spray preparation, a transdermal preparation, an ointment, and a suppository), and others.

Please replace the paragraph beginning at page 20, line 24, with the following rewritten paragraph:

[0038] The liquid preparation (including a jelly and a gumdrop-like

preparation~~gumi~~) may be prepared, depending on a dosage form, by mixing (e.g., dissolving, suspending (dispersing), and emulsifying) the active ingredients with a liquid carrier component (e.g., an aqueous solvent such as purified water, an oily solvent, a gel base (e.g., an aqueous or oily gel)), and if necessary an additive (e.g., an emulsifier, a dispersant or suspension, an isotonizing agent, a solubilizer, a preservative, a stabilizer, a flavoring substance, a pH control agent (pH regulator), and a buffer), and if desired, the mixture is sterilized. The ointment may be prepared by mixing or kneading the active ingredients with a carrier component (e.g., an oily base, an aqueous base) (and if necessary an additive), if desired under heating.